Alloplex Biotherapeutics
Alloplex is clinical stage biotechnology company developing an innovative and differentiated approach to cellular immunotherapy that employs an ex vivo immune cell training platform that is compatible with but does not require genetic engineering. Our lead program deriving from this platform is directed towards treating cancer and is comprised of highly activated therapeutic cells called SUPLEXA, an individualized product made from the patient’s peripheral blood without any genetic engineering.
